Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma

por Flynt, Erin, Bisht, Kamlesh, Sridharan, Vinidhra, Ortiz, María, Towfic, Fadi, Thakurta, Anjan
Publicado 2020

Developing next generation immunomodulatory drugs and their combinations in multiple myeloma

por Thakurta, Anjan, Pierceall, William E., Amatangelo, Michael D., Flynt, Erin, Agarwal, Amit
Publicado 2021

Nanopore sequencing of single-cell transcriptomes with scCOLOR-seq

por Philpott, Martin, Watson, Jonathan, Thakurta, Anjan, Brown, Tom, Brown, Tom, Oppermann, Udo, Cribbs, Adam P.
Publicado 2021

RF19 | PSUN349 Histone Eraser and Reader Targeting Epigenetic Inhibitors Are Effective in Pancreatic Neuroendocrine Tumours

por Carmichael, James, Escoubet, Laure, Lines, Kate, Mavrommatis, Konstantinos, Mortensen, Deborah, Thakker, Rajesh V, Thakurta, Anjan
Publicado 2022

Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways

por Karagoz, Kubra, Stokes, Matthew, Ortiz-Estévez, María, Towfic, Fadi, Flynt, Erin, Gooding, Sarah, Pierceall, William, Thakurta, Anjan
Publicado 2022

Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathways

por Ortiz-Estévez, María, Towfic, Fadi, Flynt, Erin, Stong, Nicholas, Jang, In Sock, Wang, Kai, Trotter, Matthew W. B., Thakurta, Anjan
Publicado 2021

Differential RNA splicing as a potentially important driver mechanism in multiple myeloma

por Bauer, Michael A., Ashby, Cody, Wardell, Christopher, Boyle, Eileen M., Ortiz, Maria, Flynt, Erin, Thakurta, Anjan, Morgan, Gareth, Walker, Brian A.
Publicado 2020

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM

por Stong, Nicholas, Ortiz-Estévez, María, Towfic, Fadi, Samur, Mehmet, Agarwal, Amit, Corre, Jill, Flynt, Erin, Munshi, Nikhil, Avet-Loiseau, Hervé, Thakurta, Anjan
Publicado 2023

A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples

por Ren, Yan, Wang, Maria, Couto, Suzana, Hansel, Donna E., Miller, Karen, Lopez-Girona, Antonia, Bjorklund, Chad C., Gandhi, Anita K., Thakurta, Anjan, Chopra, Rajesh, Breider, Michael
Publicado 2016

The Next Frontier: Translational Development of Ubiquitination, SUMOylation, and NEDDylation in Cancer

por Pellegrino, Nicole E., Guven, Arcan, Gray, Kayleigh, Shah, Punit, Kasture, Gargi, Nastke, Maria-Dorothea, Thakurta, Anjan, Gesta, Stephane, Vishnudas, Vivek K., Narain, Niven R., Kiebish, Michael A.
Publicado 2022

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma

por Ansari-Pour, Naser, Samur, Mehmet, Flynt, Erin, Gooding, Sarah, Towfic, Fadi, Stong, Nicholas, Estevez, Maria Ortiz, Mavrommatis, Konstantinos, Walker, Brian, Morgan, Gareth, Munshi, Nikhil, Avet-Loiseau, Herve, Thakurta, Anjan
Publicado 2023

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with...

por Bjorklund, Chad C., Kang, Jian, Amatangelo, Michael, Polonskaia, Ann, Katz, Mark, Chiu, Hsiling, Couto, Suzana, Wang, Maria, Ren, Yan, Ortiz, Maria, Towfic, Fadi, Flynt, J. Erin, Pierceall, William, Thakurta, Anjan
Publicado 2019

Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase...

por Gandhi, Anita K, Kang, Jian, Havens, Courtney G, Conklin, Thomas, Ning, Yuhong, Wu, Lei, Ito, Takumi, Ando, Hideki, Waldman, Michelle F, Thakurta, Anjan, Klippel, Anke, Handa, Hiroshi, Daniel, Thomas O, Schafer, Peter H, Chopra, Rajesh
Publicado 2014

Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group

por Samur, Mehmet Kemal, Aktas Samur, Anil, Fulciniti, Mariateresa, Szalat, Raphael, Han, Tessa, Shammas, Masood, Richardson, Paul, Magrangeas, Florence, Minvielle, Stephane, Corre, Jill, Moreau, Philippe, Thakurta, Anjan, Anderson, Kenneth C., Parmigiani, Giovanni, Avet-Loiseau, Hervé, Munshi, Nikhil C.
Publicado 2020

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma

por Gooding, Sarah, Ansari-Pour, Naser, Kazeroun, Mohammad, Karagoz, Kubra, Polonskaia, Ann, Salazar, Mirian, Fitzsimons, Evie, Sirinukunwattana, Korsuk, Chavda, Selina, Ortiz Estevez, Maria, Towfic, Fadi, Flynt, Erin, Pierceall, William, Royston, Daniel, Yong, Kwee, Ramasamy, Karthik, Vyas, Paresh, Thakurta, Anjan
Publicado 2022

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine

por Döhner, Hartmut, Wei, Andrew H., Roboz, Gail J., Montesinos, Pau, Thol, Felicitas R., Ravandi, Farhad, Dombret, Hervé, Porkka, Kimmo, Sandhu, Irwindeep, Skikne, Barry, See, Wendy L., Ugidos, Manuel, Risueño, Alberto, Chan, Esther T., Thakurta, Anjan, Beach, C.L., Lopes de Menezes, Daniel
Publicado 2022

Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity

por Gandhi, Anita K, Mendy, Derek, Waldman, Michelle, Chen, Gengxin, Rychak, Emily, Miller, Karen, Gaidarova, Svetlana, Ren, Yan, Wang, Maria, Breider, Michael, Carmel, Gilles, Mahmoudi, Afshin, Jackson, Pilgrim, Abbasian, Mahan, Cathers, Brian E, Schafer, Peter H, Daniel, Tom O, Lopez-Girona, Antonia, Thakurta, Anjan, Chopra, Rajesh
Publicado 2014

Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma

por Mikulasova, Aneta, Ashby, Cody, Tytarenko, Ruslana G., Qu, Pingping, Rosenthal, Adam, Dent, Judith A., Ryan, Katie R., Bauer, Michael A., Wardell, Christopher P., Hoering, Antje, Mavrommatis, Konstantinos, Trotter, Matthew, Deshpande, Shayu, Yaccoby, Shmuel, Tian, Erming, Keats, Jonathan, Auclair, Daniel, Jackson, Graham H., Davies, Faith E., Thakurta, Anjan, Morgan, Gareth J., Walker, Brian A.
Publicado 2020

Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma

por Sudha, Parvathi, Ahsan, Aarif, Ashby, Cody, Kausar, Tasneem, Khera, Akhil, Kazeroun, Mohammad H., Hsu, Chih-Chao, Wang, Lin, Fitzsimons, Evelyn, Salminen, Outi, Blaney, Patrick, Czader, Magdalena, Williams, Jonathan, Abu Zaid, Mohammad I., Ansari-Pour, Naser, Yong, Kwee L., van Rhee, Frits, Pierceall, William E., Morgan, Gareth J., Flynt, Erin, Gooding, Sarah, Abonour, Rafat, Ramasamy, Karthik, Thakurta, Anjan, Walker, Brian A.
Publicado 2022

Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma

por Kurata, Keiji, James-Bott, Anna, Tye, Mark A., Yamamoto, Leona, Samur, Mehmet K., Tai, Yu-Tzu, Dunford, James, Johansson, Catrine, Senbabaoglu, Filiz, Philpott, Martin, Palmer, Charlotte, Ramasamy, Karthik, Gooding, Sarah, Smilova, Mihaela, Gaeta, Giorgia, Guo, Manman, Christianson, John C., Payne, N. Connor, Singh, Kritika, Karagoz, Kubra, Stokes, Matthew E., Ortiz, Maria, Hagner, Patrick, Thakurta, Anjan, Cribbs, Adam, Mazitschek, Ralph, Hideshima, Teru, Anderson, Kenneth C., Oppermann, Udo
Publicado 2023